Searchable abstracts of presentations at key conferences in endocrinology

ea0006s14 | Melanocortin receptors | SFE2003

Brain melanocortin receptors - feeding and energy expenditure

Small C

The hypothalamic melanocortin system consists of an endogenous antagonist, agouti related protein (Agrp) and agonist, alpha-melanocyte stimulating hormone (alpha-MSH), which act at the hypothalamic melanocortin 3 and 4 receptors. CNS administration of Agrp increased food intake over a 24-h period. Agrp blocked the reduction in 1-h food intake observed following alpha-MSH administration. This effect occurred independently of whether the antagonist was administered simultaneousl...

ea0005s14 | Apoptosis/Survival Signalling | BES2003

Phosphoinositide 3-kinase dependent lipid signals in cellular survival responses

Downes C

Type I phosphoinositide 3-kinases (PI3Ks)are regulated by tyrosine kinases, Ras and G-protein coupled receptors and generate the lipid second messenger, phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 regulates a bewildering variety of cellular responses primarily through binding and hence activating or targeting a range of proteins each of which posseses a specific PIP3 binding module, most commonly a pleckstrin homology (PH) domain. In terms of cell survival the key ...

ea0005s17 | Dominant Endocrine Cancer Syndromes | BES2003

VHL and HIF, a basis for VHL pathogenesis

Pugh C

The interplay between the von Hippel Lindau (VHL) protein and hypoxia-inducible factor (HIF) will be reviewed and the extent to which this explains the pathogenesis of VHL disease will be discussed.HIF is a master regulator of the transcriptional response to diminished tissue oxygenation, controlling such processes as angiogenesis, erythropoietin production, cellular metabolism and influencing cell proliferation / survival decisions. HIF itself is a heterodimer, dominantly...

ea0028p281 | Reproduction | SFEBES2012

FSH glycosylation in women with polycystic ovary syndrome (PCOS) undergoing ovulation induction

Tracey C , Laura C , Chapman A

Clomiphene is commonly first-line treatment for ovulation induction in women with PCOS. Clomiphene results in a rise in serum FSH concentration; its effect upon FSH glycosylation is less clear. Glycosyl components of serum gonadotrophins are important determinants of their bioactivity.We compared serum FSH glycosylation in blood samples taken from healthy women with regular ovulatory cycles (group A; n=8) and anovulatory women before (group B; ...

ea0029p1749 | Thyroid (non-cancer) | ICEECE2012

A case of subacute thyroiditis in a patient on Adalimumab for treatment of refractory palmo-plantar pustular psoriasis

Chiriac A. , Miron C. , Foia L. , Chiriac A. , Solovan C. , Ancuta C.

We describe a case of subacute thyroiditis in a psoriatic patient treated with Adalimumab, with a very good clinical evolution with nonsteroidal anti-inflamatory medication.Tumor necrosis factor alpha (TNF-α) is a pleiotropic cytokine produced by a variety of cells, comprehending T lymphocytes. TNF-α mediates its effects through two receptors, known as p55 (TNF-R1), and p75 (TNF-R2). TNF-α plays a primary role in both the induction and the...

ea0011p353 | Diabetes, metabolism and cardiovascular | ECE2006

The metabolic syndrome and insulin resistance in polycystic ovary syndrome – study over 40 patients

Neamtu C , Gherlan I , Boanta C , Caragheorgheopol A , Dumitrache C

Insulin resistance is possibly playing an underlying pathogenic role in the polycystic ovary syndrome (PCOS) and although is not a part of its definition, it appears in 50-90% of PCOS women. Polycystic ovary syndrome is also frequently associated with obesity; women suffering of PCOS seem to be at a great risk of developing a metabolic syndrome.Objectives: The aim of our study was to determine the prevalence of the metabolic syndrome in a population of 4...

ea0029p154 | Bone & Osteoporosis | ICEECE2012

Endoscopic comparison of esophageal and gastroduodenal mucosal effects of enterocoating alendronate with calcitriol combined drug and alendronate in Korean postmenopausal women

Mok J. , Yu C. , Lee C.

Introduction: The study was a single-center, open label, randomized, head-to-head clinical study to compare the mucosal findings after perform esophagogastroduodenoscopy between two groups before and after use of alendronate only and enterocoating alendronate (5 mg) with calcitriol (0.5 μg) combined drug (Maxmarvil).Methods: The 33 postmenopausal healthy volunteers, aged 50–70 years (mean age: 58±5 years) without gastrointestinal symptoms ...

ea0026p426 | Thyroid (non cancer) | ECE2011

Triiodothyronine stimulates cystatin C production and glucose transport in bone cells

Schmid Ch , Ghirlanda C , Zwimpfer C

Background: Thyroid hormones increase both serum levels of cystatin C and renal glomerular filtration rate (reflected by lower serum creatinine); the latter is considered the main determinant of cystatin C levels. A potential explanation for this apparently discrepant finding is an increased production, rather than a decreased clearance, of cystatin C. To study whether 3,3′,5-triiodo-L-thyronine (T3) increases the production of cystatin C in a w...

ea0019p102 | Clinical practice/governance and case reports | SFEBES2009

Propylthiouracil-induced antineutrophilic cytoplasmic antibody-positive vasculitis

Bravis V , Kong C , Johnston C

A 38-year old lady from the Philippines presented with a 2-year history of a painless thyroid lump, without pressure symptoms. Over the previous year it had gradually enlarged in size. She gave a history of disturbed sleep, tremor, anxiety and weight loss over the 2-year period. Past medical history included right middle lobectomy for bronchiectasis 10 years previously. Thyroid function tests revealed TSH<0.05 mu/l, FT4 86 pmol/l, FT3 18.3 pmol/l and ...

ea0017oc12 | Diabetes 1 | BSPED2008

HbA1c league tables? How to get promoted and avoid relegation!

Elder C , Hinchliffe C , Wright N

Background: Since the DCCT demonstrated that improved glycaemic control reduced complications the goal of diabetes management has been to maintain HbA1c as close to normal as possible. Recent changes by the laboratory to our HbA1c assay, combined with the debate about deanonymised publication of clinic’s HbA1c results, creating the potential for ‘league tables’, focussed our attention on the variation between HbA1c assays.Clinical data: Ou...